Tweet You will note there is no ProfK, ProfG, NDG etc on this one because they declined to participate because they were unwilling to randomise any MS-newbie onto a lower efficacy agent. This decision is vindicated by the findings that people randomised to lower efficacy…
It’s no secret the world thinks Morning People are better than those of us who dgaf about a sunrise. Never mind that people who own leafblowers and the majority of serial killers are statistically more likely to be early risers. I’ve never been a Morning…
Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely…
By Nicole Robinson Living with multiple sclerosis has changed the way I look at a lot of things, especially what it means to celebrate myself. For a long time, I didn’t think of myself as someone who needed to be … Continue reading → Source:…
A new partnership aims to advance software that uses artificial intelligence (AI) to examine brain MRI scans for signs characteristic of multiple sclerosis (MS). Neurophet said it will work with the Vall d’Hebron Institut de Recerca (VHIR), the research institute of Vall d’Hebron University Hospital…
Tweet ProfG rediscovered the idea if we focus on hand function loss rather than leg function we would have found a treatment years ago because the nerves in the leg accumulate damage more and exhaust the capacity to compensate for MS, because it is a…
An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with someone more experienced may help them feel more confident in managing their condition, with self-reported psychological benefits for both people in the pairing. That’s according to five-year…
Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called…
Tweet I have made the point that the action of anti-CD20 antibodies is probably in the blood and not in the CNS. A trial of double/treble dose of ocrelizumab to help get into the CNS failed to show any extra benefit over the standard dose.…
MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Chris Pero as June’s … Continue reading → Source:…